Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: A randomized, multicenter, controlled trial

Chest

Volumn 137, Issue 2, 2010, Pages 254-262

  Wang, Chen ^a   Zhai, Zhenguo ^a   Yang, Yuanhua ^a   Wu, Qi ^b   Cheng, Zhaozhong ^c   Liang, Lirong ^a   Dai, Huaping ^a   Huang, Kewu ^a   Lu, Weixuan ^d   Zhang, Zhonghe ^e   Cheng, Xiansheng ^f   Shen, Ying H ^g  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Medical College of Qingdao Universty   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

^f FUWAI HOSPITAL   (China)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; NADROPARIN; WARFARIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATALITY; FEMALE; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; RANDOMIZED CONTROLLED TRIAL;

EID: 76749101547     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0765     Document Type: Article

References (38)

1. Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest. 1989;95(5)(Suppl):282S-289S.
2. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. An overview. Chest. 1994;106(3):725-726.
3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6) (Suppl):454S-545S.
4. Torbicki A, Perrier A, Konstantinides S, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276-2315.
5. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2(8606):293-298.
6. Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet. 1986;2(8512):886-889.
7. Braithwaite BD, Birch PA, Poskitt KR, Heather BP, Earnshaw JJ . Accelerated thrombolysis with high dose bolus t-PA extends the role of peripheral thrombolysis but may increase the risks. Clin Radiol. 1995;50(11):747-750.
8. Levine MN. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Chest. 1991;99(4)(Suppl):128S-134S.
9. Ross AM, Gao R, Coyne KS, et al; TUCC Investigators . A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J. 2001;142(2):244-247.
10. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138(1 Pt 1):39-44.
11. Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest. 1992;101(4)(Suppl):183S-185S.
12. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997; 80(2):184-188.
13. Ashton RW, Daniels CE, Ryu JH. Thrombolytic therapy in patients with submassive pulmonary embolism. N Engl J Med. 2003;348(4):357-359.
14. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest. 2004;125(4):1539-1545.
15. Zhu L, Yang YH, Wu YF, Zhai ZG, Wang C; National Project of the Diagnosis and Treatment Strategies for Pulmonary Thromboembolism investigators. Value of transthoracic echocardiography combined with cardiac troponin I in risk stratification in acute pulmonary thromboembolism. Chin Med J (Engl). 2007;120(1):17-21.
16. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115(6): 1695-1707.
17. Goldhaber SZ. Thrombolysis in venous thromboembolism. An international perspective. Chest. 1990;97(4)(Suppl):176S-181S.
18. Stein PD, Coleman RE, Gottschalk A, Saltzman HA, Terrin ML, Weg JG. Diagnostic utility of ventilation/perfusion lung scans in acute pulmonary embolism is not diminished by pre-existing cardiac or pulmonary disease. Chest. 1991;100(3):604-606.
19. Parker JA, Markis JE, Palla A, et al. Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Radiology. 1988;166(2): 441-445.
20. Qanadli SD, El Hajjam M, Vieillard-Baron A, et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol. 2001;176(6):1415-1420.
21. van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235(3):798-803.
22. Capstick T, Henry MT. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J. 2005; 26(5):864-874.
23. Baruah DB, Dash RN, Chaudhari MR, Kadam SS. Plasminogen activators: a comparison. Vascul Pharmacol. 2006;44(1): 1-9.
24. Agnelli G, Parise P. Bolus thrombolysis in venous thromboembolism. Chest. 1992;101(4)(Suppl):172S-182S.
25. Meyer G, Collignon MA, Guinet F, Jeffrey AA, Barritault L , Sors H. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med. 1990;17(6-8):315-319.
26. Goldhaber SZ, Agnelli G, Levine MN; The Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest. 1994;106(3):718-724.
27. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest. 1994; 106(3):712-717.
28. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol. 1998;31(5): 1057-1063.
29. Miller GA, Sutton GC. Acute massive pulmonary embolism. Clinical and haemodynamic findings in 23 patients studied by cardiac catheterization and pulmonary arteriography. Br Heart J. 1970;32(4):518-523.
30. Tow DE, Simon AL. Comparison of lung scanning and pulmonary angiography in the detection and follow-up of pulmonary embolism: the Urokinase-Pulmonary Embolism Trial experience. Prog Cardiovasc Dis. 1975;17(4):239-245.
31. Morgenthaler TI, Ryu JH. Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc. 1995;70(5):417-424.
32. Lim KE, Chan CY, Chu PH, Hsu YY, Hsu WC. Right ventricular dysfunction secondary to acute massive pulmonary embolism detected by helical computed tomography pulmonary angiography. Clin Imaging. 2005;29(1): 16-21.
33. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W ; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.
34. Meyer G, Sors H, Charbonnier B, et al; The European Cooperative Study Group for Pulmonary Embolism. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992;19(2):239-245.
35. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20(1):24-30.
36. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. 1997;18(7):1141-1148.
37. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111(5):1241-1245.
38. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embo lism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386-1389.